The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

Flosequinanum     7-fluoro-3-methoxysulfanyl-1- methyl...

Synonyms: SureCN1651722, AC1L1F33, AC1Q4GF7, AC1Q4NY5, UNII-6NB119DLU7
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of FLOSEQUINAN

 

High impact information on FLOSEQUINAN

  • This trial was designed to determine whether the addition of oral flosequinan, a new direct-acting arterial and venous vasodilator with possible dose-dependent positive inotropic effects, improves exercise tolerance and quality of life in such patients [1].
  • One hundred ninety-three patients with chronic heart failure (New York Heart Association functional class II or III and left ventricular ejection fraction < 40%) receiving digoxin and diuretic drugs were randomly assigned (double-blind) to the addition of flosequinan (100 mg once daily, n = 93) or placebo (n = 100) for 3 months [5].
  • After baseline hemodynamic measurements using balloon-tipped pulmonary artery and radial arterial catheters, patients were randomized to receive 50, 100 or 150 mg of flosequinan daily [6].
  • Maximal oxygen consumption increased by 1.7 ml/kg per min in the flosequinan group (n = 17) but by only 0.6 ml/kg per min in the placebo group (n = 23), p = 0.05 between the groups [5].
  • Flosequinan is a new vasodilator drug that acts by interfering with the inositol-triphosphate/protein kinase C pathway, an important mechanism of vasoconstriction [5].
 

Chemical compound and disease context of FLOSEQUINAN

 

Biological context of FLOSEQUINAN

 

Anatomical context of FLOSEQUINAN

 

Associations of FLOSEQUINAN with other chemical compounds

 

Gene context of FLOSEQUINAN

  • Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans [21].
  • Two hundred eighteen patients with stable heart failure (ejection fraction [EF] <35%) and in New York Heart Association (NYHA) class III to IV had MLC-1 measured at baseline and 1 month after being randomized to the direct vasodilator flosequinan or placebo [22].
  • Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan [22].
  • Flosequinan increased exercise time more with the fixed protocol, so after 5 weeks' treatment exercise time was the same with both protocols; 680 (64) s with the Bruce and 673 (147) s with the fixed protocol [23].
  • 3. Neither flosequinan (n = 12) nor BTS 53 554, its sulphone metabolite (n = 6) produced a positive inotropic effect or altered the time course of contraction in myocardium from the hearts of patients with end-stage failure [15].
 

Analytical, diagnostic and therapeutic context of FLOSEQUINAN

References

  1. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Massie, B.M., Berk, M.R., Brozena, S.C., Elkayam, U., Plehn, J.F., Kukin, M.L., Packer, M., Murphy, B.E., Neuberg, G.W., Steingart, R.M. Circulation (1993) [Pubmed]
  2. Effect of flosequinan in patients with acute-onset heart failure complicating acute myocardial infarction. Schneeweiss, A., Wynne, R.D., Marmor, A. Crit. Care Med. (1989) [Pubmed]
  3. Effect of flosequinan on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat. Jones, R.B., Frodsham, G., Dickinson, K., Foster, G.A. Br. J. Pharmacol. (1993) [Pubmed]
  4. Cardiovascular effects of the novel arteriovenous dilator agent, flosequinan in conscious dogs and cats. Sim, M.F., Yates, D.B., Parkinson, R., Cooling, M.J. Br. J. Pharmacol. (1988) [Pubmed]
  5. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study. Packer, M., Narahara, K.A., Elkayam, U., Sullivan, J.M., Pearle, D.L., Massie, B.M., Creager, M.A. J. Am. Coll. Cardiol. (1993) [Pubmed]
  6. Sustained hemodynamic response to flosequinan in patients with heart failure receiving angiotensin-converting enzyme inhibitors. Gottlieb, S.S., Kukin, M.L., Penn, J., Fisher, M.L., Cines, M., Medina, N., Yushak, M., Taylor, M., Packer, M. J. Am. Coll. Cardiol. (1993) [Pubmed]
  7. Sulphoxide reduction by rat intestinal flora and by Escherichia coli in vitro. Lee, S.C., Renwick, A.G. Biochem. Pharmacol. (1995) [Pubmed]
  8. A comparison of the metabolic effects of flosequinan and propranolol in patients with non-insulin-dependent diabetes mellitus. Lewis, H.M., Kendall, M.J., Wright, A.D., Bratty, J.R., Maxwell, S. Journal of clinical pharmacy and therapeutics. (1991) [Pubmed]
  9. Effect of flosequinan on exercise capacity and symptoms in severe heart failure. Elborn, J.S., Stanford, C.F., Nicholls, D.P. British heart journal. (1989) [Pubmed]
  10. Flosequinan, a new vasodilator: systemic and coronary hemodynamics and neuroendocrine effects in congestive heart failure. Cavero, P.G., De Marco, T., Kwasman, M., Lau, D., Liu, M., Chatterjee, K. J. Am. Coll. Cardiol. (1992) [Pubmed]
  11. Positive inotropic and lusitropic effects of intravenous flosequinan in patients with heart failure. Burstein, S., Semigran, M.J., Dec, G.W., Boucher, C.A., Fifer, M.A. J. Am. Coll. Cardiol. (1992) [Pubmed]
  12. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy. Dakak, N., Makhoul, N., Merdler, A., Yechiely, H., Kahana, L., Halon, D.A., Schneeweiss, A., Lewis, B.S. Eur. Heart J. (1993) [Pubmed]
  13. The electrophysiological effects of flosequinan. Bashir, Y., O'Nunain, S., Paul, V.E., Butrous, G.S., Ward, D.E., Camm, A.J. Eur. Heart J. (1991) [Pubmed]
  14. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure. Thomas, P., O'Gorman, D.J., Sheridan, D.J. British journal of clinical pharmacology. (1993) [Pubmed]
  15. Differential inotropic effects of flosequinan in ventricular muscle from normal ferrets versus patients with end-stage heart failure. Perreault, C.L., Hague, N.L., Loh, E., Hunneyball, I.M., Sim, M.F., Morgan, J.P. Br. J. Pharmacol. (1992) [Pubmed]
  16. Flosequinan, a vasodilator with a novel mechanism of action. Resnick, M.S., Maitland, L.A., Morgan, K.G. Br. J. Pharmacol. (1991) [Pubmed]
  17. Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle. Frodsham, G., Jones, R.B. Eur. J. Pharmacol. (1992) [Pubmed]
  18. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure. Silke, B., Tennet, H., Fischer-Hansen, J., Keller, N., Heikkila, J., Salminen, K. Eur. Heart J. (1992) [Pubmed]
  19. Novel drugs and current therapeutic approaches in the treatment of heart failure. Bonarjee, V.V., Dickstein, K. Drugs (1996) [Pubmed]
  20. Chiral inversion of drug: role of intestinal bacteria in the stereoselective sulphoxide reduction of flosequinan. Kashiyama, E., Yokoi, T., Todaka, T., Odomi, M., Kamataki, T. Biochem. Pharmacol. (1994) [Pubmed]
  21. Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans. Kashiyama, E., Yokoi, T., Odomi, M., Funae, Y., Inoue, K., Kamataki, T. Drug Metab. Dispos. (1997) [Pubmed]
  22. Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Hansen, M.S., Stanton, E.B., Gawad, Y., Packer, M., Pitt, B., Swedberg, K., Rouleau, J.L. Am. J. Cardiol. (2002) [Pubmed]
  23. Exercise tolerance in patients with heart failure--how should it be measured? Cowley, A.J., Fullwood, L., Stainer, K., Hampton, J.R. Eur. Heart J. (1991) [Pubmed]
  24. The effects of flosequinan on regional blood flow in normal man. Scott, R.A., Woods, K.L., Barnett, D.B. British journal of clinical pharmacology. (1991) [Pubmed]
  25. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan. Massie, B.M., Shah, N.B., Pitt, B., Packer, M. Am. Heart J. (1996) [Pubmed]
  26. Effects of low-dose flosequinan on left ventricular systolic and diastolic chamber performance. Starling, M.R. Am. Heart J. (1994) [Pubmed]
 
WikiGenes - Universities